Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Debt Ratio (2018 - 2024)

Neurocrine Biosciences filings provide 6 years of Debt Ratio readings, the most recent being 0.04 for Q1 2024.

  • On a quarterly basis, Debt Ratio changed N/A to 0.04 in Q1 2024 year-over-year; TTM through Mar 2024 was 0.04, a N/A change, with the full-year FY2023 number at 0.05, down 26.85% from a year prior.
  • Debt Ratio hit 0.04 in Q1 2024 for Neurocrine Biosciences, down from 0.05 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.28 in Q3 2020 to a low of 0.04 in Q1 2024.
  • Median Debt Ratio over the past 4 years was 0.07 (2022), compared with a mean of 0.12.
  • The widest YoY moves for Debt Ratio: up 24.43% in 2023, down 26.85% in 2023.
  • Neurocrine Biosciences' Debt Ratio stood at 0.28 in 2020, then tumbled by 74.72% to 0.07 in 2022, then dropped by 26.85% to 0.05 in 2023, then crashed by 32.4% to 0.04 in 2024.
  • The last three reported values for Debt Ratio were 0.04 (Q1 2024), 0.05 (Q4 2023), and 0.06 (Q3 2023) per Business Quant data.